Can a Two-Drug punch revive immunotherapy for tough bladder cancers?
NCT ID NCT06439836
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether adding an experimental drug called emavusertib (CA-4948) to the immunotherapy pembrolizumab can help patients with advanced urothelial cancer whose tumors have become resistant to PD-1/PD-L1 blockers. The study will enroll 27 adults and focus on finding the safest dose and checking for side effects, while also watching for any signs that the combination might shrink tumors. It is currently recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emavusertib (CA-4948) combined with pembrolizumab
What this could lead to
If successful, this could point toward a new treatment option for patients whose urothelial cancer has stopped responding to standard immunotherapy.
What could go wrong
This is a very early Phase 1 trial with only 27 people, so safety and the right dose are the main goals—not yet proof of effectiveness. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory Saint Joseph's Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Phone: •••-•••-••••
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
Contact
Contact Phone: •••-•••-••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-••••
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYP/Weill Cornell Medical Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact Phone: •••-•••-••••
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
RECRUITINGOrange, California, 92868, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
RECRUITINGIrvine, California, 92612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UT Southwestern/Simmons Cancer Center-Dallas
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-••••